- Home
- / Alterity Therapeutics
Alterity Therapeutics
Stock Price
$0
2024-10-28
Market Capitalization
$15.7 M
2024-10-28
Alterity Therapeutics Summary
Company Summary
- Overview
- Alterity Therapeutics is a company researching and developing therapies to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurodegenerative disorders. Its drug candidate, ATH434, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- Melbourne, AU | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Lawrence Gozlan, Non-Executive Director
Peter Marks, Non-Executive Director
Kathryn Andrews, Chief Financial Officer
LocationsView all
2 locations detected
Melbourne, VIC HQ
Australia
level 3/460 Bourke St
Newark, CA
United States
39899 Balentine Dr #360
Alterity Therapeutics Financials
Summary Financials
- Gross profit (H1, 2026)
- $2.8M
- Net income (H1, 2026)
- ($9.6M)
- Cash (H1, 2026)
- $49.2M
- EBIT (H1, 2026)
- ($10.4M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026